Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyHealth Plan Upper Ohio Drug Testing Update | OpenP…
    Ask Trek AI about this page
    CurrentHealth Plan of the Upper Ohio Valley, Inc.Policy N/A

    Clinical Drug Testing in Addiction Treatment Programs and Pain Management Programs

    Customize your policy alerts

    Sign up for all healthplanofupperohiovalley policy alerts

    Know when healthplanofupperohiovalley releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs the medical necessity, documentation, coding, and prior authorization requirements for presumptive and definitive drug testing used in chronic pain management and substance use disorder treatment or recovery programs. It applies across all lines of business, with distinct authorization rules for WV Medicaid, Medicare, commercial fully insured, and self-funded plans.

    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley, Inc.
    PolicyClinical Drug Testing in Addiction Treatment Programs and Pain Management Programs
    Policy CodePolicy N/A
    Change TypeRevisedcoding and WV Medicaid authorization updates
    Effective Date7/24/2025
    Next Review Date7/24/2026
    Key ActionObtain prior authorization for WV Medicaid presumptive tests exceeding 24 combined tests per calendar year.
    SourceLink
    POLICY UPDATE CHANGES

    Authorization requirements for WV Medicaid were updated during a policy revision.

    CPT/HCPCS coding was updated to add codes 0007U and 0051U.

    CMS and BMS criteria and related billing and coding references were reviewed or updated.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    24Combined annual presumptive-test limit before authorization
    12Annual G0480 definitive tests allowed without authorization
    3Presumptive testing codes
    5Definitive testing codes addressed
    3Treatment phases defined
    All linesPolicy applicability

    Medical Necessity Criteria

    Presumptive Testing

    Presumptive testing may be considered medically necessary when ALL of the following are met.

    Presumptive testing medical necessity

    • Required clinical assessment: The clinical assessment includes the individual's diagnosis, history, and physical or behavioral examination.
    • Interpretation capability: The clinician has knowledge of test interpretation.
    • Clinical-use plan: A plan is in place for using the testing findings clinically.

      Documentation must show how the results will impact treatment.

    Continuation Monitoring

    Additional presumptive testing may be considered medically necessary when ALL of the following are met.

    Ongoing presumptive monitoring: Testing is performed during the stabilization or maintenance phase to monitor adherence and progression.Stabilization: 31–90 days of abstinence; maintenance: more than 90 consecutive days of abstinence.

    Documentation must show how the results will impact treatment.

    Definitive Testing Indications

    Definitive testing may be considered medically necessary when ANY of the following situations applies, with supporting medical-record documentation.

    Qualifying indication for definitive testing

    • Clinical purpose: A specific substance must be detected because it was not identified by presumptive testing, the substance level must be quantified, or improved accuracy of the result is needed.
    • Decision-impacting result: The results will inform clinical decisions with major clinical or non-clinical implications, such as a treatment transition, medication-therapy change, or change in legal status.
    • Disputed presumptive result: The patient disputes a presumptive test.

    Definitive Testing Medical Necessity

    Definitive testing for substance use disorder treatment requires ALL of the following documentation and treatment-impact criteria.

    Definitive testing medical necessity

    • Treatment context: Document the stage of treatment and whether the patient is receiving initial treatment or is experiencing a relapse.
    • Clinical findings and prior testing: Document examination findings and previous test results, including recent documented substance use, patient-disclosed use, random or scheduled testing, presumptive test findings, and signs and symptoms supporting definitive testing when the presumptive test is negative.
    • Medication inventory: Document all medications, supplements, and herbal products the patient is taking.
    • External testing purpose:

    Definitive testing should not be performed solely to confirm a substance expected to be present on a presumptive test. For example, definitive testing is not appropriate solely to confirm a presumptive positive for Suboxone when the patient is taking Suboxone.

    Covered Codes and Coding Rules

    Covered CPT CodesCPTCovered
    80305Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only, including sample validation when performed, per date of service.
    80306Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; read by instrument-assisted direct optical observation, including sample validation when performed, per date of service.
    80307Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers, chromatography, and mass spectrometry with or without chromatography, including sample validation when performed, per date of service.
    Additional Drug Testing CodesCPT
    0007UDrug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine; includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service.
    0051UPrescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31-drug panel, reported as quantitative results, detected or not detected, per date of service.
    Covered HCPCS CodesHCPCSCovered
    G0480Definitive drug test using drug identification methods able to identify individual drugs and distinguish structural isomers; includes required internal standards, calibration and matrix-matched quality control, specimen validity testing, qualitative or quantitative, all sources, per day; 1-7 drug classes including metabolites if performed.
    G0481Definitive drug test using the specified identification, internal-standard, calibration, and quality-control methods; includes specimen validity testing, qualitative or quantitative, all sources, per day; 8-14 drug classes including metabolites if performed.
    G0482Definitive drug test using the specified identification, internal-standard, calibration, and quality-control methods; includes specimen validity testing, qualitative or quantitative, all sources, per day; 15-21 drug classes including metabolites if performed.
    G0483Definitive drug test using the specified identification, internal-standard, calibration, and quality-control methods; includes specimen validity testing, qualitative or quantitative, all sources, per day; 22 or more drug classes including metabolites if performed.
    G0659Definitive drug test using identification methods able to identify individual drugs and distinguish structural isomers, excluding immunoassays and enzymatic methods, performed without method- or drug-specific calibration, matrix-matched quality control, or stable isotope or other recognized internal standards; qualitative or quantitative, all sources, includes specimen validity testing, per specimen, any number of drug classes.
    Annual Presumptive Testing Limit
    Annual limit24 presumptive tests in combination per calendar year
    Tests includedCPT 80305, 80306, and 80307
    Authorization thresholdMore than 24 tests in a calendar year requires prior authorization
    WV Medicaid G0480 Annual Limit
    PlanWV Medicaid
    CodeG0480 definitive drug testing
    Annual limit without authorization

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    WV Medicaid Presumptive Testing Limit

    For WV Medicaid, presumptive drug screens (CPT 80305, 80306, and 80307) are limited to 24 tests in combination per calendar year. Obtain prior authorization from The Health Plan before exceeding the applicable annual benefit limit.

    • Codes: 80305, 80306, 80307
    • Limit: 24 combined presumptive screens per calendar year
    Prior Authorization

    WV Medicaid G0480 Annual Limit

    WV Medicaid limits definitive drug screens billed with HCPCS G0480 to 12 tests per calendar year without authorization. Obtain medical-necessity prior authorization before exceeding the annual limit.

    • Code: G0480
    • Limit: 12 tests per calendar year without authorization

    Clinical Role of Drug Testing

    Drug testing in pain management and substance use disorder treatment should provide a clinical determination that informs the treatment plan and reflects the patient’s treatment stage and current presentation. Presumptive testing identifies the presence or absence of drug classes, while definitive testing identifies specific substances or metabolites and may quantify their concentrations. Definitive testing is used when a specific substance is not identified by presumptive methods, quantification or improved accuracy is needed, results may affect significant clinical or non-clinical decisions, or the patient disputes a presumptive result.

    Treatment Phases and Testing Types

    Beginning or Induction Phase
    PhaseBeginning or induction phase
    Abstinence durationLess than 30 days of abstinence
    Treatment classificationPhase of treatment
    Middle or Stabilization Phase
    PhaseMiddle or stabilization phase
    Abstinence duration31–90 days of abstinence
    Treatment classificationPhase of treatment

    Covered Testing Indications

    Presumptive Drug Testing

    Presumptive drug testing may be considered medically necessary for individuals in chronic pain or substance use disorder programs when ALL of the following are met.

    Covered presumptive testing indication

    • Clinical assessment: The clinical assessment includes the individual's diagnosis, history, and physical or behavioral examination.
    • Interpretation capability: The clinician has knowledge of test interpretation.
    • Clinical-use plan: A plan is in place regarding how the testing findings will be used clinically.
    • Treatment impact:

    Testing Frequency and Authorization Thresholds

    Presumptive Testing Frequency Limit
    Codes80305, 80306, and 80307
    Combined annual limit24 presumptive tests in combination per calendar year
    Prior authorizationMore than 24 tests in a calendar year requires prior authorization
    WV Medicaid G0480 Frequency Limit
    PlanWV Medicaid
    CodeG0480
    Annual limit without authorization12 tests per calendar year

    Laboratory Ordering Guidance

    Billing Rule

    Communicate definitive-testing needs to the laboratory

    When ordering definitive testing, advise the testing laboratory if a particular substance or group of substances is suspected or expected. Because laboratories do not all automatically reflex positive presumptive results, a specific order for definitive testing may be required.

    • Communicate the suspected or expected substance or substance group to the laboratory.
    • Confirm whether the laboratory requires a separate definitive-testing order.

    Excluded Testing

    Not covered: Definitive testing performed solely to confirm a substance expected to be present on a presumptive test, such as confirming a presumptive positive for Suboxone in a patient taking Suboxone.

    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley, Inc.
    PolicyClinical Drug Testing in Addiction Treatment Programs and Pain Management Programs
    Policy CodePolicy N/A
    Change TypeRevisedcoding and WV Medicaid authorization updates
    Effective Date7/24/2025
    Next Review Date7/24/2026
    Key ActionObtain prior authorization for WV Medicaid presumptive tests exceeding 24 combined tests per calendar year.
    SourceLink
    On This Page
    Medical Necessity CriteriaCovered Codes and Coding RulesAuthorization, Documentation, and Denial RisksClinical Role of Drug TestingTreatment Phases and Testing TypesCovered Testing IndicationsTesting Frequency and Authorization ThresholdsLaboratory Ordering GuidanceExcluded Testing
    Document whether the testing is court ordered or being performed for employment purposes.
  1. Treatment modification: The results are expected to modify the treatment plan by affecting the level of care or the patient's continuation or discontinuation from the treatment program.
  2. 12 tests per calendar year
    G0480 Authorization Threshold
    Applicable plansMedicare, commercial fully insured, and self-funded plans
    CodeG0480
    Authorization thresholdPrior authorization is required for 12 or more definitive tests of 7 or fewer drug classes within a calendar year
    Expanded Definitive Panel Threshold
    Applicable plansMedicare, commercial fully insured, and self-funded plans
    Drug-class scopeMore than 7 drug classes
    Authorization requirementPrior authorization is required for all definitive tests assessing more than 7 drug classes
    Prior Authorization

    WV Medicaid G0481-G0482 Authorization

    WV Medicaid requires prior authorization for every request billed with G0481 or G0482. Submit specific justification for the testing, and ensure that justification is documented in the medical record.

    • Codes: G0481 and G0482
    • Include specific testing justification and corresponding medical-record documentation
    Prior Authorization

    WV Medicaid G0659 Authorization

    Definitive testing billed with G0659 requires prior authorization beginning with the initial date of service. Do not delay authorization until the service exceeds an annual limit.

    • Code: G0659
    • Authorization is required from the initial date of service

    Unsupported block type: prior_auth

    Prior Authorization

    G0480 Authorization Threshold

    Obtain prior authorization when 12 or more definitive tests assessing 7 or fewer drug classes are ordered within a calendar year under Medicare or commercial coverage.

    • Code: G0480
    • Threshold: 12 or more tests in a calendar year
    • Scope: 7 or fewer drug classes
    Prior Authorization

    Expanded Definitive Panel Authorization

    Prior authorization is required for all definitive tests assessing more than 7 drug classes. This includes expanded panels billed with G0481, G0482, G0483, or G0659.

    • Codes: G0481, G0482, G0483, G0659
    • Scope: more than 7 drug classes
    Prior Authorization

    Non-Participating Provider Authorization

    Non-participating laboratories and providers must obtain prior authorization for all services related to drug testing in addiction treatment and pain management programs.

    • Applies to all related drug-testing services
    • Applies to non-participating laboratories and providers
    Documentation Required

    Presumptive Testing Record Requirements

    Before ordering presumptive testing, document a clinical assessment that includes the diagnosis, history, and physical or behavioral examination. The record must also show that the clinician understands test interpretation, has a plan for using the findings clinically, and will use results to affect treatment.

    • Diagnosis, history, and physical/behavioral examination
    • Clinician knowledge of test interpretation
    • Plan for clinical use of results
    • Document how results will impact treatment
    Documentation Required

    Definitive Testing Medical Record Requirements

    For definitive testing, clearly document the stage of treatment; whether the patient is in initial treatment or experiencing relapse; examination findings; prior results; recent or disclosed substance use; testing type; presumptive findings and any symptoms supporting testing after a negative result; medications, supplements, and herbal products; and whether testing is court-ordered or employment-related.

    • Document treatment stage and initial treatment versus relapse
    • Include examination findings and previous test results
    • Record recent or disclosed use, random or scheduled testing, and presumptive findings
    • List medications, supplements, and herbal products
    • Identify court-ordered or employment-related testing when applicable
    Documentation Required

    Treatment-Impact Documentation

    Document the anticipated treatment impact of definitive-test results. The record must explain whether results could change the patient’s level of care or lead to continuation or discontinuation from the treatment program.

    • Explain potential impact on level of care
    • Explain potential impact on continuation or discontinuation from the program
    Documentation Required

    Audit-Ready Medical Record

    Maintain medical records that reflect the applicable medical-necessity criteria. The Health Plan may audit this documentation at any time under the provider agreement, including after payment.

    • Records must support medical necessity
    • Documentation is subject to post-payment audit by The Health Plan
    Denial Risk

    Missing Presumptive Testing Medical Necessity Documentation

    Presumptive testing may be denied when the record lacks the required clinical assessment or does not establish the clinician’s interpretation capability, planned clinical use of results, and expected treatment impact.

    • Include diagnosis, history, and physical/behavioral examination
    • Document how test findings will be used and how they will affect treatment
    Denial Risk

    Insufficient Definitive Testing Justification

    Definitive testing may be denied when the medical record does not establish the treatment stage, initial-treatment or relapse status, relevant examination and prior results, suspected clinical need, and anticipated treatment impact.

    • Document the clinical context and rationale for definitive testing
    • Explain the expected effect on level of care or treatment-program participation
    Denial Risk

    Confirmation of Expected Presumptive-Positive Substance

    Do not order definitive testing solely to confirm a substance that is expected to be present on the presumptive test, such as confirming a presumptive-positive result for Suboxone in a patient taking Suboxone.

    • Definitive testing is intended for substances not identified by presumptive methods, quantification, disputed results, or consequential clinical decisions
    • Advise the laboratory when a particular substance or substance group is suspected or expected
    Denial Risk

    Missing Required Prior Authorization

    Services subject to a prior-authorization requirement may be denied if authorization is not obtained before the applicable threshold or required date of service. Verify the payer, code, drug-class count, annual utilization, and provider-network status before testing.

    • WV Medicaid presumptive testing: authorization above the applicable 24-test limit
    • WV Medicaid G0480: authorization above 12 tests per calendar year
    • WV Medicaid G0481-G0482: authorization for all requests
    • WV Medicaid G0659: authorization from the initial date of service
    • Commercial and Medicare: authorization thresholds and expanded-panel requirements
    Denial Risk

    Drug-Class Panel Must Match Clinical History

    Select a panel whose number of drug classes correlates with regional exposure and the patient’s known history of drug abuse. Do not order a panel broader than the documented clinical exposure or patient history supports.

    • Document suspected or expected substances when ordering definitive testing
    • Match the panel scope to regional exposure and known drug-abuse history
    Maintenance Phase
    PhaseMaintenance phase
    Abstinence durationMore than 90 consecutive days of abstinence
    Treatment classificationPhase of treatment
    Presumptive/Qualitative Testing
    Testing typePresumptive/qualitative testing
    PurposeDetermines the presence or absence of drugs or drug classes in a urine sample
    Result formatResults are expressed as negative, positive, or a numerical result
    Definitive/Quantitative Testing
    Testing typeDefinitive/quantitative testing
    PurposeIdentifies specific medications, illicit substances, and metabolites
    Analyte reportingAnalytes are reported as absent or present, typically at concentrations such as ng/mL
    The medical record documents how the results will impact treatment.

    Definitive Testing

    Definitive testing may be considered medically necessary when ANY of the following indications applies and the clinical rationale and anticipated treatment impact are documented.

    Covered definitive testing indication

    • Specific substance or quantification need: A specific substance is not identified by presumptive testing, quantification of the substance level is needed, or improved accuracy of the result is needed.
    • Major decision impact: The results will inform a clinical or non-clinical decision with major implications for the patient, including treatment transition, medication-therapy changes, or changes in legal status.
    • Disputed presumptive result: The patient disputes a presumptive test.
    G0480 Authorization Threshold
    PlansMedicare, commercial fully insured, and self-funded plans
    Code and scopeG0480 for definitive tests of 7 or fewer drug classes
    Authorization thresholdPrior authorization is required at 12 or more tests within a calendar year